APP and Alzheimer disease: Two of these 19 proteins, acetylcholinesterase (ACHE) and APP, are known anti-AD drugs targets, corresponding to 17 existing drugs [Table 1, S6 Table], including three approved drugs for AD treatment (galantamine, rivastigmine and donepezil).